Zobrazeno 1 - 10
of 402
pro vyhledávání: '"Per, Pfeiffer"'
Autor:
Anne L. H. Bisgaard, Carsten Brink, Tine Schytte, Rana Bahij, Mathilde Weisz Ejlsmark, Uffe Bernchou, Anders S. Bertelsen, Per Pfeiffer, Faisal Mahmood
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Background and purposeBiomarkers for prediction of outcome in patients with pancreatic cancer are wanted in order to personalize the treatment. This study investigated the value of longitudinal diffusion-weighted magnetic resonance imaging (DWI) for
Externí odkaz:
https://doaj.org/article/28104d735b244123a85c34d678a8bda1
Autor:
Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of
Externí odkaz:
https://doaj.org/article/340dd2f28c5441ddaf0adaf8e0022afa
Autor:
Lene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, Sören Möller, Ida Coordt Elle, Morten Ladekarl, Camilla Qvortrup, Per Pfeiffer
Publikováno v:
EClinicalMedicine, Vol 70, Iss , Pp 102521- (2024)
Summary: Background: Trifluridine-tipiracil has shown a survival benefit compared with placebo in patients with chemorefractory metastatic esophago-gastric adenocarcinoma. We aimed to compare the efficacy of trifluridine-tipiracil plus bevacizumab vs
Externí odkaz:
https://doaj.org/article/e459d21f02454465ad6e11bbad319d13
Autor:
Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen, Per Pfeiffer
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6820-6837 (2023)
Pancreatic cancer is rising as one of the leading causes of cancer-related death worldwide. Patients often present with advanced disease, limiting curative treatment options and therefore making management of the disease difficult. Systemic chemother
Externí odkaz:
https://doaj.org/article/84c8ef3ae4404d2e855f9ea004735ac8
Autor:
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled
Externí odkaz:
https://doaj.org/article/9b0b9ded99b04bf2a4fe11a35852398d
Autor:
Martina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Camilla Qvortrup
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median pr
Externí odkaz:
https://doaj.org/article/9adf36b11bbe47b08440d13fbaa65f3d
Autor:
Ismail Gögenur, Per Pfeiffer, Tobias Freyberg Justesen, Line Schmidt Tarpgaard, Camilla Qvortrup
Publikováno v:
BMJ Open, Vol 13, Iss 6 (2023)
Introduction Within the last two decades, major advances have been made in the surgical approach for patients with colorectal cancer. However, to this day we face considerable challenges in reducing surgery-related complications and improving long-te
Externí odkaz:
https://doaj.org/article/8674965e001d4362b1abbf938b3d793b
Autor:
Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. Hochster
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) has shown efficacy and tolerability in refractory metastatic colorectal cancer (mCRC). Because randomized controlled trial (RCT) data comparing FTD/TPI + BEV with FTD/TPI are lacking
Externí odkaz:
https://doaj.org/article/96c8a39f041a48ffb9a10c68d06ec9e4
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is used in the palliative treatment of peritoneal metastasis. The combination of intraperitoneal and systemic chemotherapy seems rational, and the aim of this systematic rev
Externí odkaz:
https://doaj.org/article/26814e8cd1c24f72a0e0bdfcffca97c9
Autor:
Emerik Osterlund, Ari Ristimäki, Soili Kytölä, Teijo Kuopio, Eetu Heervä, Timo Muhonen, Päivi Halonen, Raija Kallio, Leena-Maija Soveri, Jari Sundström, Mauri Keinänen, Annika Ålgars, Raija Ristamäki, Halfdan Sorbye, Per Pfeiffer, Luís Nunes, Tapio Salminen, Annamarja Lamminmäki, Markus J. Mäkinen, Tobias Sjöblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundKRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this sp
Externí odkaz:
https://doaj.org/article/decb120b6a4a470ea68f4e7d8f7c7d6d